Liquidia Technologies Inc
Healthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | |
|---|---|---|---|
| Revenue | $8.1M | $2.7M | $7.3M |
| Operating income | −$46.8M | −$34.9M | −$28.0M |
| Net income | −$47.6M | −$53.1M | −$29.2M |
| Total assets | $68.8M | $49.4M | $14.8M |
| Total liabilities | $33.9M | $30.7M | $48.5M |
| Equity | $34.9M | $18.7M | −$33.7M |
| EPS (diluted) | $-2.59 | $-7.51 | $-51.78 |
| Shares out. | 15.6M | 15.5M | 563,076 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- −580.1%
- Net margin
- −589.5%
- Return on equity
- −136.2%
- Return on assets
- −69.1%
- Return on capital (ROCE)
- −90.1%
- Liabilities / assets
- 49.2%
- Debt / equity
- 0.97×
- Book value / share
- $2.25
- Revenue growth (YoY)
- 198.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Altman Z″ (distress)
- -7.66distress
- Accruals / assets
- 1.0%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2025-03-20A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
- Phase 3Active Not Recruitingreadout ~2025-05-31Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
- Phase 3Recruitingreadout ~2029-07A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Director / officer change · Amended charter or bylaws · Other material eventNov 18, 2020
- Shareholder vote · Other material eventNov 16, 2020
- Results of operationsNov 9, 2020
- Other material eventNov 2, 2020
- Other material eventOct 19, 2020
- Other material eventOct 14, 2020
- Director / officer changeAug 20, 2020
- Results of operationsAug 10, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/ASCHEDULE 13G HOLDINGS REPORT AMENDMENTFeb 16, 2021
- 15-12BNov 30, 2020
- 4FORM 4 SUBMISSIONNov 27, 2020
- 4FORM 4 SUBMISSIONNov 25, 2020
- 4FORM 4 SUBMISSIONNov 24, 2020
- EFFECTNov 20, 2020
- EFFECTNov 20, 2020
- 4FORM 4 SUBMISSIONNov 20, 2020
- 144Nov 20, 2020
- 25-NSENov 18, 2020
- POS AMNov 18, 2020
- POS AMNov 18, 2020
- S-8 POSNov 18, 2020
- S-8 POSNov 18, 2020
- S-8 POSNov 18, 2020